Agile Therapeutics,Inc. (NASDAQ:AGRX) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Results of Operations and Financial Condition
On July28, 2017, Agile Therapeutics,Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June30, 2017 and an update on the Company’s operations for the same period. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit99.1.
In accordance with General Instruction B.2 of Form8-K, the information included in this Current Report on Form8-K (including Exhibit99.1 hereto), shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description |
99.1 |
Press release issued by Agile Therapeutics,Inc. dated July28, 2017. |